Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

por Deng, Li-Juan, Zhou, Ke-Shu, Liu, Li-Hong, Zhang, Ming-Zhi, Li, Zhi-Ming, Ji, Chun-Yan, Xu, Wei, Liu, Ting, Xu, Bing, Wang, Xin, Gao, Su-Jun, Zhang, Hui-Lai, Hu, Yu, Li, Yan, Cheng, Ying, Yang, Hai-Yan, Cao, Jun-Ning, Zhu, Zun-Min, Hu, Jian-Da, Zhang, Wei, Jing, Hong-Mei, Ding, Kai-Yang, Zhang, Xiang-Yang, Zhao, Ren-Bin, Zhang, Bin, Tian, Ya-Min, Song, Yong-Ping, Song, Yu-Qin, Zhu, Jun
Publicado 2023

A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria

por Zhang, Lu, Dong, Yu-jun, Peng, Hong-ling, Li, Hao, Zhang, Ming-zhi, Wang, Hui-han, Liu, Qin-hua, Su, Li-ping, Zhong, Li-ye, Wu, Wen-jun, Huang, Liang, Yan, Xiao-jing, Fan, Lei, Tang, Wen-jiao, Li, Zhen-ling, Bi, Lin-tao, Li, Yan, Gao, Guang-xun, Gao, Li, Liu, Ting-bo, Wei, Yong-qiang, Liu, Yao, Yu, Li, Zhou, Hui, Sun, Chun-yan, Qian, Wen-bin, Zou, De-hui, Zhang, Hui-lai, Ding, Kai-yang, Wang, Xiao-bo, Bai, Ou, Huang, Wen-rong, Chen, Bing, Yang, Lin, Song, Jia, Gao, Da, Chen, Tong, Luo, Jun, Wang, Shu-ye, Ma, Liang-ming, Fajgenbaum, David C., Li, Jian
Publicado 2023